Silver Spring, Maryland—(ENEWSPF)—September 11, 2014. The U.S. Food and Drug Administration yesterday approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
